Gemini Therapeutics (NASDAQ:GMTX) Stock Price Up 1.6% - Still a Buy?

Key Points

• Shares rose 1.6% in mid-day trading to $67.30 (intraday high $67.44) on volume of ~321,530 shares, a 70% increase versus the average daily volume.
• Valuation and technicals: the company has a market capitalization of $2.92 billion and a negative P/E of -67.30, trading above its 50‑day SMA ($65.58) but below its 200‑day SMA ($75.86).
• Business focus: Gemini is a clinical-stage biotechnology firm developing integrin-targeting antibody therapies for fibrotic diseases, with lead programs in chronic kidney disease and idiopathic pulmonary fibrosis.

Shares of Gemini Therapeutics, Inc. (NASDAQ:GMTX - Get Free Report) rose 1.6% during mid-day trading on Friday . The stock traded as high as $67.44 and last traded at $67.30. Approximately 321,530 shares were traded during mid-day trading, an increase of 70% from the average daily volume of 189,291 shares. The stock had previously closed at $66.27.

Gemini Therapeutics Trading Up 1.6%

The business's 50 day simple moving average is $65.58 and its two-hundred day simple moving average is $75.86. The firm has a market capitalization of $2.92 billion, a PE ratio of -67.30 and a beta of -0.12.

About Gemini Therapeutics

Gemini Therapeutics NASDAQ: GMTX is a clinical‐stage biotechnology company focused on the discovery and development of integrin‐targeting therapies for fibrotic diseases. Leveraging a proprietary antibody discovery platform, Gemini identifies and optimizes highly selective inhibitors of integrin subunits that play a key role in activating transforming growth factor‐β (TGF-β), a central driver of tissue fibrosis. The company's approach is designed to block fibrotic signaling at its source, potentially offering improved safety and efficacy profiles compared with broader anti‐fibrotic agents.

Gemini's lead programs are directed toward chronic kidney disease and idiopathic pulmonary fibrosis, two areas with significant unmet medical need and limited treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.